July 3, 2022

BREAKING NEWS

FDA Warns About Possible Increased Risk of Death and Serious Side Effects with Cancer Drug Copiktra (Duvelisib)

FDA Authorizes Revisions to Evusheld Dosing

ASH 2021: Association Between the Leukemia Mortality-to-Incidence Ratio and State Geographic Healthcare Disparities in the United States

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Support Groups | Researchers

Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Support Groups | Researchers

June 14, 2022

June 14, 2022

ASH 2021: Dr. Alexey Danilov on SYK Inhibitor Entospletinib in Combination with Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

Chairman of the Board and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the final results of a phase 1/2 clinical trial of entospletinib combined with obinutuzumab in patients with relapsed/refractory CLL.

June 14, 2022

Ask Me Anything – Featuring Dr. Brian Koffman and Michele Nadeem-Baker

Dr. Brian Koffman participates in CLL Society’s new Facebook Live event to answer your questions on anything. With no prepared presentation as a part of this event, it is truly a time dedicated to get answers on COVID-19 precautions for the immunocompromised, his treatment journey, the building of CLL

CLL SOCIETY FAST FIND

One click to our most popular content.

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL DOCTORS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

QUICK LINKS

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL DOCTORS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

June 14, 2022

ASH 2021: Dr. Alexey Danilov on SYK Inhibitor Entospletinib in Combination with Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

Ask Me Anything – Featuring Dr. Brian Koffman and Michele Nadeem-Baker

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT